prikaz prve stranice dokumenta A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
  Preuzmi
PDF 600.76 KB
Znanstveni rad - Izvorni znanstveni rad
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
Journal of Neurology, 271 (2024), 9; 5813-5824. https://doi.org/10.1007/s00415-024-12518-7
Lal, Anoushka P.; Foong, Yi Chao; Sanfilippo, Paul G.; Spelman, Tim; Rath, Louise; Levitz, David; Fabis-Pedrini, Marzena; Foschi, Matteo; Habek, Mario; Kalincik, Tomas; Roos, Izanne; Lechner-Scott, Jeannette; John, Nevin; Soysal, Aysun; D’Amico, Emanuele; Gouider, Riadh; Mrabet, Saloua; Gross-Paju, Katrin; Cárdenas-Robledo, Simón; Moghadasi, Abdorreza Naser; Sa, Maria Jose; Gray, Orla; Oh, Jiwon; Reddel, Stephen; Ramanathan, Sudarshini; Al-Harbi, Talal; Altintas, Ayse; Hardy, Todd A.; Ozakbas, Serkan; Alroughani, Raed; Kermode, Allan G.; Surcinelli, Andrea; Laureys, Guy; Eichau, Sara; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Hodgkinson, Suzanne; Ramo-Tello, Cristina; Maimone, Davide; McCombe, Pamela; Spitaleri, Daniele; Sanchez-Menoyo, Jose Luis; Yetkin, Mehmet Fatih; Baghbanian, Seyed Mohammad; Karabudak, Rana; Al-Asmi, Abdullah; Jakob, Gregor Brecl; Khoury, Samia J.; Etemadifar, Masoud; van Pesch, Vincent; Buzzard, Katherine; Taylor, Bruce; Butzkueven, Helmut; Van der Walt, Anneke Više autora...

Citirajte ovaj rad

Lal, A. P., Foong, Y. C., Sanfilippo, P. G., Spelman, T., Rath, L., Levitz, D. ... Van der Walt, A. (2024). A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology, 271. (9), 5813-5824. doi: 10.1007/s00415-024-12518-7

Lal, Anoushka P., et al. "A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic." Journal of Neurology, vol. 271, br. 9, 2024, str. 5813-5824. https://doi.org/10.1007/s00415-024-12518-7

Lal, Anoushka P., Yi Chao Foong, Paul G. Sanfilippo, Tim Spelman, Louise Rath, David Levitz, Marzena Fabis Pedrini, et al. "A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic." Journal of Neurology 271, br. 9 (2024): 5813-5824. https://doi.org/10.1007/s00415-024-12518-7

Lal, A. P., et al. (2024) 'A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic', Journal of Neurology, 271(9), str. 5813-5824. doi: 10.1007/s00415-024-12518-7

Lal AP, Foong YC, Sanfilippo PG, Spelman T, Rath L, Levitz D, i sur.. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology [Internet]. 27.06.2024. [pristupljeno 19.12.2024.];271(9):5813-5824. doi: 10.1007/s00415-024-12518-7

A. P. Lal, et al., "A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic", Journal of Neurology, vol. 271, br. 9, str. 5813-5824, Lipanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:528442. [Citirano: 19.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:528442
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
AutorAnoushka P. Lal
AutorYi Chao Foong
AutorPaul G. Sanfilippo
AutorTim Spelman
AutorLouise Rath
AutorDavid Levitz
AutorMarzena Fabis-Pedrini
AutorMatteo Foschi
AutorMario Habek
AutorTomas Kalincik
AutorIzanne Roos
AutorJeannette Lechner-Scott
AutorNevin John
AutorAysun Soysal
AutorEmanuele D’Amico
AutorRiadh Gouider
AutorSaloua Mrabet
AutorKatrin Gross-Paju
AutorSimón Cárdenas-Robledo
AutorAbdorreza Naser Moghadasi
AutorMaria Jose Sa
AutorOrla Gray
AutorJiwon Oh
AutorStephen Reddel
AutorSudarshini Ramanathan
AutorTalal Al-Harbi
AutorAyse Altintas
AutorTodd A. Hardy
AutorSerkan Ozakbas
AutorRaed Alroughani
AutorAllan G. Kermode
AutorAndrea Surcinelli
AutorGuy Laureys
AutorSara Eichau
AutorAlexandre Prat
AutorMarc Girard
AutorPierre Duquette
AutorSuzanne Hodgkinson
AutorCristina Ramo-Tello
AutorDavide Maimone
AutorPamela McCombe
AutorDaniele Spitaleri
AutorJose Luis Sanchez-Menoyo
AutorMehmet Fatih Yetkin
AutorSeyed Mohammad Baghbanian
AutorRana Karabudak
AutorAbdullah Al-Asmi
AutorGregor Brecl Jakob
AutorSamia J. Khoury
AutorMasoud Etemadifar
AutorVincent van Pesch
AutorKatherine Buzzard
AutorBruce Taylor
AutorHelmut Butzkueven
AutorAnneke Van der Walt
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA NEUROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset. Methods: A multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018-March 10 2020) and post-pandemic onset (March 11 2020-11 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6 months of last use. Results: Post-pandemic onset, there was a significant increase in DMT initiation/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39-2.13; switching: OR 1.66, 95% CI 1.40-1.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09-1.87; switching: OR 1.67, 95% CI 1.41-1.98)]. Anti-CD20mAb initiation/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06-1.49; Switching: OR 1.15, 95% CI 1.02-1.29. Initiation/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41-0.73; switching: OR 0.49, 95% CI 0.41-0.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41-0.57; switching: OR 0.78, 95% CI 0.62-0.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15-0.48; switching: OR 0.27, 95% CI 0.17-0.44)]. Conclusions: Post-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Neurology
Brojčani podacivol. 271, br. 9, str. 5813-5824
p-ISSN0340-5354
e-ISSN1432-1459
DOIhttps://doi.org/10.1007/s00415-024-12518-7
URN:NBNurn:nbn:hr:105:528442
Datum objave publikacije2024-06-27
URL dokumentahttps://link.springer.com/10.1007/s00415-024-12518-7
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-12-17 10:36:27